emocha’s $6.2 million Series A raise was recently featured in Fierce Healthcare, and emocha CEO Sebastian Seiguer spoke about the continuing challenge of medication adherence. “I find it absolutely mind-blowing that medication non-adherence would continue to exist as dramatically as it does,” Seiguer said. emocha’s program measures true, dose-by-dose adherence, rather than often-used metrics like refill rates. Seiguer advocates for a more precise measure of adherence. “In some cases, patients should refill their medication—that’s a great thing,” Seiguer said. “But the amount of confusion, the number of medication errors that happen, it’s unbelievable to me. It’s an urgent problem.”